Axsome Thera (AXSM)

$183.72 -2.46 (-1.32%)
Market Cap 9.26B
Revenue (ttm) 385.69M
Net Income (ttm) -287.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 540.35
Profit Margin -74.47%
Debt to Equity Ratio 1.60
Volume 573,800
Avg Vol 654,764
Day's Range N/A - N/A
Shares Out 50.41M
Stochastic %K 52%
Beta 0.40
Analysts Strong Sell
Price Target $217.00

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 332 3241
Fax: 212 320 0245
Address:
One World Trade Center, 22nd Floor, New York, United States
Willdowdell
Willdowdell Feb. 23 at 3:36 PM
$AXSM How about getting the SG&A expenses under control? This has been a chronic problem with these guys
0 · Reply
Mike826_1999
Mike826_1999 Feb. 23 at 3:16 PM
$AXSM Morgan Stanley. Auvelity: The key question is no longer can AUVELITY grow, but how durable growth remains as the base scales and whether operating leverage begins to emerge. Sensitivity will hinge on volume growth vs. gross to net, persistence, and the incremental impact of potential AD agitation approval layered onto an already scaled franchise. ii) Cost structure: SG&A rose in FY25 (+39% YoY) driven by sales force exp (~600 reps), DTC investment, and the SYMBRAVO launch, while R&D modestly declined as several late stage trials completed. 2026 becomes a proof year for oper lev: if rev continues to compound, SG&A growth should decelerate. Any revenue miss would be magnified given the higher fixed cost base, increasing stock sensitivity to comm execution. iii) 2026 is catalyst dense: Axsome transitions from a single asset commercial story to a multi asset earnings and pipeline platform. Positive regulatory or late stage clinical outcomes could materially expand the revenue base.
0 · Reply
jlfromli
jlfromli Feb. 23 at 2:52 PM
$AXSM Missed it Wanted $170. Oh, well. Still have my Swing open
0 · Reply
NatureboyRay
NatureboyRay Feb. 23 at 2:49 PM
$AXSM that price action in the morning had me worried. Looks like earnings are OK. Wooooo!
0 · Reply
pi22dv7
pi22dv7 Feb. 23 at 2:38 PM
$AXSM picked up at 173.85, thanks weak hands.
0 · Reply
Mike826_1999
Mike826_1999 Feb. 23 at 2:38 PM
$AXSM Was able to pick some up at $174.
2 · Reply
11thestate
11thestate Feb. 23 at 2:20 PM
Did you know? Only around 25% of eligible investors usually file in settlements like $AXSM’s $7.75M payout. Stat: If that happens here, the estimated $0.46 per share could possibly increase to about $1.84 per share, depending on how many investors actually submit valid claims. Fact: If you bought between May 10, 2021 and April 22, 2022, you can submit a late claim here: https://11th.com/cases/axsome-investor-settlement
0 · Reply
quickaspeter
quickaspeter Feb. 23 at 2:07 PM
$AXSM April 30 is coming! 💥🚀💰💰💰
0 · Reply
quickaspeter
quickaspeter Feb. 23 at 2:05 PM
$AXSM Good data…ending on Friday the 13th 😅💥🚀💰
0 · Reply
chainma1l
chainma1l Feb. 23 at 1:57 PM
$AXSM I was in a meeting an missed the call. Anything about outside the US progress? Go for it, assholes, take out all the stop losses! I WILL JLFROMLI your asses without a second thought!
1 · Reply
Latest News on AXSM
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

Feb 17, 2026, 7:00 AM EST - 6 days ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

Jan 27, 2026, 7:00 AM EST - 27 days ago

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline

Jan 24, 2026, 6:38 AM EST - 4 weeks ago

Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline

MoneyShow's Best Investment Ideas For 2026: Part 2

Jan 12, 2026, 4:20 PM EST - 5 weeks ago

MoneyShow's Best Investment Ideas For 2026: Part 2

BDX BRO BX CALM

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars

Dec 31, 2025, 10:30 AM EST - 7 weeks ago

FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

Dec 31, 2025, 6:55 AM EST - 7 weeks ago

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 4, 2025, 6:18 PM EST - 2 months ago

Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Nov 20, 2025, 7:00 AM EST - 3 months ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Nov 6, 2025, 7:00 AM EST - 3 months ago

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Nov 6, 2025, 7:00 AM EST - 3 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

FBIO

Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer

Nov 5, 2025, 3:12 PM EST - 3 months ago

Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer

Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 2:46 PM EST - 3 months ago

Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript

Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 24, 2025, 11:20 AM EDT - 4 months ago

Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating

Oct 10, 2025, 4:07 AM EDT - 4 months ago

Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

Oct 9, 2025, 7:00 AM EDT - 4 months ago

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

Oct 7, 2025, 7:00 AM EDT - 4 months ago

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Sep 18, 2025, 1:53 AM EDT - 5 months ago

Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Sep 17, 2025, 7:00 AM EDT - 5 months ago

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 5:49 PM EDT - 5 months ago

Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Aug 5, 2025, 1:40 PM EDT - 7 months ago

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 2:50 PM EDT - 7 months ago

Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 7:00 AM EDT - 7 months ago

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy

Jul 25, 2025, 1:46 PM EDT - 7 months ago

Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Jul 21, 2025, 7:30 AM EDT - 7 months ago

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 8 months ago

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Jul 7, 2025, 7:00 AM EDT - 8 months ago

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Jun 20, 2025, 7:00 AM EDT - 8 months ago

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Jun 11, 2025, 7:00 AM EDT - 9 months ago

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

May 27, 2025, 7:00 AM EDT - 9 months ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

May 13, 2025, 7:00 AM EDT - 10 months ago

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

May 6, 2025, 12:48 PM EDT - 10 months ago

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

May 5, 2025, 11:44 AM EDT - 10 months ago

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

May 5, 2025, 10:41 AM EDT - 10 months ago

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 10 months ago

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

May 1, 2025, 7:00 AM EDT - 10 months ago

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Apr 8, 2025, 7:00 AM EDT - 11 months ago

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Apr 4, 2025, 7:00 AM EDT - 11 months ago

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Axsome's depression treatment fails to meet main goal of late-stage study

Apr 1, 2025, 7:18 AM EDT - 11 months ago

Axsome's depression treatment fails to meet main goal of late-stage study

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Mar 25, 2025, 7:13 AM EDT - 11 months ago

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Axsome: The Alzheimer's Agitation Program For AXS-05

Mar 21, 2025, 11:36 AM EDT - 1 year ago

Axsome: The Alzheimer's Agitation Program For AXS-05

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Feb 24, 2025, 1:34 PM EST - 1 year ago

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Feb 20, 2025, 8:15 AM EST - 1 year ago

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 11:12 AM EST - 1 year ago

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

Feb 11, 2025, 5:20 PM EST - 1 year ago

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

TEVA

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Feb 10, 2025, 12:33 PM EST - 1 year ago

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

TEVA

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Jan 31, 2025, 7:00 AM EST - 1 year ago

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

US FDA approves Axsome Therapeutics' migraine drug

Jan 30, 2025, 3:55 PM EST - 1 year ago

US FDA approves Axsome Therapeutics' migraine drug

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Jan 30, 2025, 3:45 PM EST - 1 year ago

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31, 2024, 9:15 AM EST - 1 year ago

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Willdowdell
Willdowdell Feb. 23 at 3:36 PM
$AXSM How about getting the SG&A expenses under control? This has been a chronic problem with these guys
0 · Reply
Mike826_1999
Mike826_1999 Feb. 23 at 3:16 PM
$AXSM Morgan Stanley. Auvelity: The key question is no longer can AUVELITY grow, but how durable growth remains as the base scales and whether operating leverage begins to emerge. Sensitivity will hinge on volume growth vs. gross to net, persistence, and the incremental impact of potential AD agitation approval layered onto an already scaled franchise. ii) Cost structure: SG&A rose in FY25 (+39% YoY) driven by sales force exp (~600 reps), DTC investment, and the SYMBRAVO launch, while R&D modestly declined as several late stage trials completed. 2026 becomes a proof year for oper lev: if rev continues to compound, SG&A growth should decelerate. Any revenue miss would be magnified given the higher fixed cost base, increasing stock sensitivity to comm execution. iii) 2026 is catalyst dense: Axsome transitions from a single asset commercial story to a multi asset earnings and pipeline platform. Positive regulatory or late stage clinical outcomes could materially expand the revenue base.
0 · Reply
jlfromli
jlfromli Feb. 23 at 2:52 PM
$AXSM Missed it Wanted $170. Oh, well. Still have my Swing open
0 · Reply
NatureboyRay
NatureboyRay Feb. 23 at 2:49 PM
$AXSM that price action in the morning had me worried. Looks like earnings are OK. Wooooo!
0 · Reply
pi22dv7
pi22dv7 Feb. 23 at 2:38 PM
$AXSM picked up at 173.85, thanks weak hands.
0 · Reply
Mike826_1999
Mike826_1999 Feb. 23 at 2:38 PM
$AXSM Was able to pick some up at $174.
2 · Reply
11thestate
11thestate Feb. 23 at 2:20 PM
Did you know? Only around 25% of eligible investors usually file in settlements like $AXSM’s $7.75M payout. Stat: If that happens here, the estimated $0.46 per share could possibly increase to about $1.84 per share, depending on how many investors actually submit valid claims. Fact: If you bought between May 10, 2021 and April 22, 2022, you can submit a late claim here: https://11th.com/cases/axsome-investor-settlement
0 · Reply
quickaspeter
quickaspeter Feb. 23 at 2:07 PM
$AXSM April 30 is coming! 💥🚀💰💰💰
0 · Reply
quickaspeter
quickaspeter Feb. 23 at 2:05 PM
$AXSM Good data…ending on Friday the 13th 😅💥🚀💰
0 · Reply
chainma1l
chainma1l Feb. 23 at 1:57 PM
$AXSM I was in a meeting an missed the call. Anything about outside the US progress? Go for it, assholes, take out all the stop losses! I WILL JLFROMLI your asses without a second thought!
1 · Reply
DonCorleone77
DonCorleone77 Feb. 23 at 1:49 PM
$AXSM Attached is a Mizuho analyst note regarding AXSM issued today.
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Feb. 23 at 1:48 PM
$AXSM 🧠 1 Hour Levels Price: $179.00 Support: $173.40 Resistance: $185.90(Possibly) 👉 Tap follow to keep these 1-hour levels on your feed.
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Feb. 23 at 1:47 PM
$AXSM Should be a good day👍🏼
0 · Reply
pi22dv7
pi22dv7 Feb. 23 at 1:39 PM
$AXSM These are great numbers to where we were 1 year ago. Q1: "Shares of common stock outstanding were 50,882,766 at December 31, 2025" - Shares outstanding is steadily increasing putting some pressure on PPS. Q2: Given the expense and cash burn, we were expecting BE by Q3 of this year, is that still on track or we see it pushing to 2027? Cheers.
0 · Reply
Crimson_Phoenix
Crimson_Phoenix Feb. 23 at 1:30 PM
$AXSM https://www.benzinga.com/news/26/02/50777011/needham-reiterates-buy-on-axsome-therapeutics-maintains-225-price-target
0 · Reply
Ramtha999
Ramtha999 Feb. 23 at 1:26 PM
$AXSM seems like a stalemate early on with little volume . Manipulators want to take it down but realize results were too good and are afraid it will backfire .
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 23 at 1:21 PM
$AXSM (-2.2% pre) Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://ooc.bz/l/94215
0 · Reply
DonCorleone77
DonCorleone77 Feb. 23 at 1:00 PM
$AXSM Axsome Therapeutics sees cash runway into cash flow positivity Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
0 · Reply
DonCorleone77
DonCorleone77 Feb. 23 at 1:00 PM
$AXSM Axsome Therapeutics reports Q4 EPS (56c), consensus (73c) Reports Q4 revenue $196M, consensus $193.26M. "Our fourth quarter and full year 2025 results demonstrate strong commercial momentum across our marketed products, and advancement and expansion of our innovative CNS pipeline, which now includes five differentiated product candidates," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics. "2026 promises to be another eventful year for Axsome with continued commercial execution, and multiple regulatory and clinical milestones including potential FDA action on our sNDA for AXS-05 in Alzheimer's disease agitation, NDA filing for AXS-12 in narcolepsy, and clinical trial progress across our development portfolio."
0 · Reply
A_Train1
A_Train1 Feb. 23 at 12:54 PM
$AXSM seems like a pretty good earnings but being punished again. Is this a repeat of last time with a sharp drop and recovery? Or is this drop going to be sustained? This market is strange.
1 · Reply
Georgejj
Georgejj Feb. 23 at 12:54 PM
$AXSM https://finance.yahoo.com/news/axsome-therapeutics-reports-fourth-quarter-120000419.html
0 · Reply
GloriaCrandall531
GloriaCrandall531 Feb. 23 at 12:53 PM
$AXSM strong relative strength holding trend line if buyers defend dips continuation setup
0 · Reply